ESR2 and breast carcinoma: The molecular pathways associated with the antiproliferative effects of ERβ are less clear; however, ERβ has been shown to reduce the expression of c-Myc while inducing the expression of the cyclin-dependent kinase inhibitor, p27Kip1, in breast cancer cells [30].